Revenue - Protagonist Therapeutics Inc (NASDAQ:PTGX) - Alpha Spread

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.92 USD 2.57% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Protagonist Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Protagonist Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Revenue
$319.1m
CAGR 3-Years
127%
CAGR 5-Years
180%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55B
CAGR 3-Years
1%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.8B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Revenue
$30.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.3B
CAGR 3-Years
16%
CAGR 5-Years
25%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.5B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
18%

See Also

What is Protagonist Therapeutics Inc's Revenue?
Revenue
319.1m USD

Based on the financial report for Jun 30, 2024, Protagonist Therapeutics Inc's Revenue amounts to 319.1m USD.

What is Protagonist Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
180%

The average annual Revenue growth rates for Protagonist Therapeutics Inc have been 127% over the past three years , 180% over the past five years .

Back to Top